Page last updated: 2024-08-18

thiophenes and Coronary Thrombosis

thiophenes has been researched along with Coronary Thrombosis in 48 studies

Research

Studies (48)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (2.08)	18.2507
2000's	12 (25.00)	29.6817
2010's	35 (72.92)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kaul, S; Krantz, MJ	1
Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cuisset, T; Grosdidier, C; Lambert, M; Loosveld, M; Loundou, AD; Morange, PE; Pankert, M; Quilici, J	1
Angiolillo, DJ; Antoniucci, D; Bernlochner, I; Hamm, C; Jaitner, J; Kastrati, A; Laugwitz, KL; Mayer, K; Morath, T; Neumann, FJ; Richardt, G; Ruf, J; Schömig, G; Schühlen, H; Schulz, S; Schunkert, H; von Merzljak, B	1
Bernlochner, I; Braun, S; Gross, L; Hadamitzky, M; Kastrati, A; Laugwitz, KL; Massberg, S; Mayer, K; Orban, M; Schulz, S; Schunkert, H; Sibbing, D	1
Goto, S; Tomita, A	1
Sabouret, P; Taiel-Sartral, M	1
Baumbach, A; Bowles, R; Butler, M; Johnson, TW; Marsden, D; Mumford, A; Mundell, S; Pike, K; Reeves, BC; Rogers, C; Strange, JW	1
Bernlochner, I; Braun, S; Hausleiter, J; Kastrati, A; Laugwitz, KL; Massberg, S; Mayer, K; Morath, T; Schulz, S; Schunkert, H; Sibbing, D	1
Boothroyd, DB; Dudley, RA; Garber, AM; Hlatky, MA; Kazi, DS; Mell, MW; Moshkevich, S; Owens, DK; Rhee, C; Shah, RU	1
Bernlochner, I; Braun, S; Hadamitzky, M; Hausleiter, J; Hoppmann, P; Kastrati, A; Laugwitz, KL; Massberg, S; Mayer, K; Mehilli, J; Morath, T; Orban, M; Schulz, S; Schunkert, H; Sibbing, D; Tiroch, K	1
Fukae, S; Izumida, S; Kawano, H; Kohno, Y; Koide, Y; Maemura, K; Takeno, M; Tsuneto, A	1
Angiolillo, DJ; Antman, EM; Braunwald, E; Corbalan, R; Dalby, AJ; Goodman, SG; McCabe, CH; Meisel, S; Murphy, SA; Purdy, DA; Verheugt, FW; Wiviott, SD	1
Farkouh, ME; Fuster, V	1
Makarov, L; Serebruany, V	1
Kereiakes, DJ	1
Grove, EL; Kristensen, SD	1
Motovska, Z; Widimsky, P	1
Makarov, LM; Serebruany, VL	1
Parra, D; Rosenstein, RS	1
Bhatt, DL	1
Unger, EF	1
Cairns, JA; Eikelboom, JW; Hirsh, J; Paikin, JS	1
Ferrandis, R; Gómez-Luque, A; Llau, JV; Sierra, P	1
Angiolillo, DJ; Tello-Montoliu, A; Tomasello, SD	1
Frey, N; Ivandic, B	1
Lancellotti, P	1
Briongos Figuero, S; de Juan-Bagudá, J; Martí-Sánchez, D; Salido-Tahoces, L	1
Hashimoto, M; Jakubowski, JA; Niitsu, Y; Ohno, K; Sugidachi, A; Tomizawa, A; Yamaguchi, S	1
Byrne, RA; Hausleiter, J; Laugwitz, KL; Orban, M; Sibbing, D	1
Ait-Mokhtar, O; Barnay, P; Bonello, L; Bonello, R; Cabassome, E; Camilleri, E; Camoin-Jau, L; Cheneau, E; Collet, F; de Labriolle, A; Dignat-George, F; Jouve, B; Maillard, L; Mancini, J; Paganelli, F; Pansieri, M; Peyre, JP; Rossi, P; Wittenberg, O	1
Andrade-Gordon, P; Chen, C; Connelly, MA; Damiano, BP; Huang, Z; Parry, TJ; Perzborn, E	1
Becker, RC; Cutlip, DE; Dauerman, HL; French, PA; Granada, JF; Price, MJ; Smyth, SS; Steinhubl, SR	1
Kern, MJ	1
Einecke, D	1
Angiolillo, DJ; Azmoon, S	1
Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A	1
Alexopoulos, D; Damelou, A; Davlouros, P; Galati, A; Hahalis, G; Kassimis, G; Makris, G; Mavronasiou, E; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I	1
Chan, KH; Chan, MY; Lee, CH; Li, Y; Low, A; Phua, QH; Richards, MA; Roe, MT; Sia, W; Sim, TB; Tai, BC; Tan, HC; Teo, SG; Yeo, TC	1
Bessereau, J; Bonello, L; Camoin-Jau, L; Collet, F; Dignat-George, F; Jouve, B; Laine, M; Lemesle, G; Maillard, L; Mancini, J; Michelet, P; Paganelli, F; Pansieri, M; Rossi, P; Wittenberg, O	1
Abtan, J; Aubry, P; Barthélémy, O; Belle, L; Beygui, F; Boueri, Z; Carrié, D; Cayla, G; Collet, JP; Cuisset, T; Elhadad, S; Henry, P; Kerneis, M; Monségu, J; Montalescot, G; Motreff, P; O'Connor, SA; Pouillot, C; Rangé, G; Rousseau, H; Sabouret, P; Saint-Etienne, C; Silvain, J; Van Belle, E; Vicaut, E	1
Chevalier, B; Diletti, R; Dorange, C; Farooq, V; Garcia-Garcia, HM; Miquel-Hebert, K; Onuma, Y; Rapoza, R; Serruys, PW; Sudhir, K; Veldhof, S	1
Coste, P; Gerbaud, E; Seguy, B	1
Aradi, D; Komócsi, A; Serebruany, VL; Vorobcsuk, A	1
Bevilacqua, M; Cirillo, P; D'Anna, C; De Rosa, R; Di Gioia, G; Galasso, G; Niglio, T; Piccolo, R; Piscione, F; Strisciuglio, T	1
Agrawal, K; Bhatt, DL	1
Cattaneo, M	1
Huber, K; Schrör, K	1
Tomoda, H	1

Reviews

15 review(s) available for thiophenes and Coronary Thrombosis

Article	Year
New antithrombotics for secondary prevention of acute coronary syndrome. Clinical cardiology, 2014, Volume: 37, Issue:3 Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Coronary Thrombosis; Dabigatran; Hemorrhage; Humans; Imines; Lactones; Morpholines; Platelet Activation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Thrombin	2014
New antiplatelet agents in the treatment of acute coronary syndromes. Archives of cardiovascular diseases, 2014, Volume: 107, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Thrombosis; Diabetes Complications; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Renal Insufficiency; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Prasugrel for arterial coronary thrombosis. Drugs of today (Barcelona, Spain : 1998), 2009, Volume: 45, Issue:2 Topics: Administration, Oral; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Coronary Thrombosis; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes	2009
Update on oral antiplatelet therapy: principles, problems and promises. Future cardiology, 2009, Volume: 5, Issue:3 Topics: Adenosine; Administration, Oral; Cardiovascular Diseases; Cilostazol; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Tetrazoles; Thiophenes; Thromboxane A2; Ticagrelor	2009
Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel. Vascular health and risk management, 2009, Volume: 5, Issue:1 Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Diabetes Complications; Drug Resistance; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stents; Thiophenes; Ticlopidine; Treatment Outcome	2009
New antithrombotic agents--insights from clinical trials. Nature reviews. Cardiology, 2010, Volume: 7, Issue:9 Topics: Adenosine; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine	2010
Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update. Vascular health and risk management, 2010, Oct-05, Volume: 6 Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Drug-Eluting Stents; Humans; Myocardial Revascularization; Perioperative Care; Perioperative Period; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2010
Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development. Expert opinion on investigational drugs, 2011, Volume: 20, Issue:1 Topics: Animals; Clopidogrel; Coronary Thrombosis; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2011
[New approaches and indications for the analysis of platelet function in cardiology]. Hamostaseologie, 2011, May-02, Volume: 31, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2011
Platelet-mediated thrombosis and drug-eluting stents. Circulation. Cardiovascular interventions, 2011, Dec-01, Volume: 4, Issue:6 Topics: Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Equipment Design; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticlopidine	2011
Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2013, Volume: 81, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Substitution; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2013
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome? Current pharmaceutical design, 2012, Volume: 18, Issue:33 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Resistance; Genotype; Hemorrhage; Humans; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Thrombosis and haemostasis, 2013, Volume: 109, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome. Angiology, 2014, Volume: 65, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Coronary Thrombosis; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticagrelor	2014
Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert review of cardiovascular therapy, 2007, Volume: 5, Issue:1 Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Interactions; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2X; Syndrome; Thiophenes; Ticagrelor; Ticlopidine	2007

Trials

8 trial(s) available for thiophenes and Coronary Thrombosis

Article	Year
The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51). Journal of the American College of Cardiology, 2013, Aug-27, Volume: 62, Issue:9 Topics: Acute Coronary Syndrome; Anticoagulants; Coronary Thrombosis; Double-Blind Method; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Myocardial Infarction; Randomized Controlled Trials as Topic; Reproducibility of Results; Rivaroxaban; Thiophenes; Treatment Outcome; United States; United States Food and Drug Administration	2013
Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REA Journal of cardiovascular translational research, 2014, Volume: 7, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Clinical Protocols; Coronary Thrombosis; Drug Administration Schedule; Fibrinolytic Agents; Germany; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Stents; Stroke; Thiophenes; Ticagrelor; Time Factors; Time-to-Treatment; Treatment Outcome	2014
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial I Circulation, 2008, Oct-14, Volume: 118, Issue:16 Topics: Administration, Oral; Aged; Clopidogrel; Coronary Thrombosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome	2008
High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. Journal of the American College of Cardiology, 2011, Jul-26, Volume: 58, Issue:5 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Blood Platelets; Coronary Thrombosis; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Phosphoproteins; Piperazines; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; ROC Curve; Sensitivity and Specificity; Stents; Thiophenes	2011
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. Journal of the American College of Cardiology, 2012, Jul-17, Volume: 60, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2012
Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention. Journal of thrombosis and thrombolysis, 2012, Volume: 34, Issue:4 Topics: Adult; Aged; Asian People; Clopidogrel; Cohort Studies; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Preoperative Care; Singapore; Thiophenes; Ticlopidine	2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting. The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22 Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Pyridines; Retreatment; Stents; Thiophenes; Ticlopidine	2012
ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatm American heart journal, 2012, Volume: 164, Issue:5 Topics: Absorbable Implants; Adult; Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Europe; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Ischemia; New Zealand; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Sample Size; Single-Blind Method; Sirolimus; Spectroscopy, Near-Infrared; Thiophenes; Tissue Scaffolds; Tomography, X-Ray Computed; Ultrasonography, Interventional	2012

Other Studies

25 other study(ies) available for thiophenes and Coronary Thrombosis

Article	Year
Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs). JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:8 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Area Under Curve; Biomarkers; Cell Adhesion Molecules; Clopidogrel; Coronary Thrombosis; Drug Resistance; Female; Hemorrhage; Humans; Logistic Models; Male; Microfilament Proteins; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Risk Assessment; Risk Factors; ROC Curve; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2013
Predictors of antiplatelet response to prasugrel during maintenance treatment. Platelets, 2015, Volume: 26, Issue:1 Topics: Aged; Blood Platelets; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Thiophenes; Treatment Outcome	2015
Point of care platelet activity measurement in primary PCI [PINPOINT-PPCI]: a protocol paper. BMC cardiovascular disorders, 2014, Apr-04, Volume: 14 Topics: Blood Platelets; Clinical Protocols; Coronary Thrombosis; Drug Monitoring; Drug Therapy, Combination; England; Hemorrhage; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Research Design; Thiophenes; Time Factors; Treatment Outcome	2014
A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry. Thrombosis and haemostasis, 2014, Volume: 112, Issue:2 Topics: Aged; Aged, 80 and over; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Thrombosis; Drug Resistance; Drug Substitution; Female; Germany; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Risk Factors; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2014
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Annals of internal medicine, 2014, Feb-18, Volume: 160, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Direct Service Costs; Drug Therapy, Combination; Drugs, Generic; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2014
Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry. Thrombosis and haemostasis, 2014, Volume: 112, Issue:6 Topics: Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Thrombosis; Female; Germany; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Recurrence; Registries; Risk Factors; Shock, Cardiogenic; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2014
Rivaroxaban therapy resulting in the resolution of right atrial thrombosis resistant to ordinary control with warfarin in a patient with atrial fibrillation. Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:6 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Coronary Thrombosis; Factor Xa Inhibitors; Heart Atria; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Vitamin K; Warfarin	2015
Acute coronary syndromes and diabetes mellitus: a winning ticket for prasugrel. Circulation, 2008, Oct-14, Volume: 118, Issue:16 Topics: Acute Coronary Syndrome; Coronary Thrombosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes	2008
Adjunctive Pharmacotherapy Part II. The Journal of invasive cardiology, 2009, Volume: 21, Issue:4 Topics: Coronary Restenosis; Coronary Thrombosis; Drug Therapy, Combination; Eptifibatide; Fibrinolytic Agents; Humans; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Prasugrel Hydrochloride; Stents; Thiophenes	2009
Future of oral antiplatelet therapy: four challenged hypotheses. Thrombosis and haemostasis, 2009, Volume: 101, Issue:6 Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Prognosis; Purinergic P2 Receptor Antagonists; Pyridines; Risk Assessment; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2009
Letter by Rosenstein and Parra regarding article, "Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inh Circulation, 2009, Jun-30, Volume: 119, Issue:25 Topics: Administration, Oral; Coronary Thrombosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes	2009
Prasugrel in clinical practice. The New England journal of medicine, 2009, Sep-03, Volume: 361, Issue:10 Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Stents; Thiophenes	2009
Weighing benefits and risks--the FDA's review of prasugrel. The New England journal of medicine, 2009, Sep-03, Volume: 361, Issue:10 Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Causality; Clinical Trials as Topic; Combined Modality Therapy; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; United States; United States Food and Drug Administration	2009
[Medication of the month. Prasugrel (Efient): potent thienopyridine antiplatelet agent]. Revue medicale de Liege, 2010, Volume: 65, Issue:11 Topics: Acute Coronary Syndrome; Coronary Thrombosis; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes	2010
[Multiple arterial thrombosis and resistance to conventional antiaggregation]. Revista espanola de cardiologia, 2011, Volume: 64, Issue:9 Topics: Aged; Angiography; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Electrocardiography; Female; Femoral Artery; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine	2011
Selective blockade of P2Y12 receptors by prasugrel inhibits myocardial infarction induced by thrombotic coronary artery occlusion in rats. Journal of cardiovascular pharmacology, 2011, Volume: 58, Issue:3 Topics: Animals; Blood Platelets; Blood Pressure; Coronary Occlusion; Coronary Thrombosis; Disease Models, Animal; Drug Evaluation, Preclinical; Electrocardiography; Heart Rate; Male; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Protein Binding; Purinergic P2 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2Y12; Thiophenes	2011
Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock. Thrombosis and haemostasis, 2011, Volume: 106, Issue:3 Topics: Aged; Angioplasty, Balloon, Coronary; Cardiopulmonary Resuscitation; Catecholamines; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Interactions; Electrocardiography; Female; Heart Arrest; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Stents; Thiophenes; Ticlopidine; Time Factors	2011
Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2011, Volume: 22, Issue:8 Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation; Carotid Artery Injuries; Coronary Occlusion; Coronary Thrombosis; Disease Models, Animal; Electrolytes; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Injections, Intravenous; Male; Morpholines; Partial Thromboplastin Time; Prothrombin Time; Rats; Rats, Sprague-Dawley; Rivaroxaban; Thiophenes	2011
"Conversations in cardiology": How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient? Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, Feb-01, Volume: 79, Issue:2 Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Decision Making; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
[Secondary prevention of myocardial infarct. A new anticoagulant improves survival prospects]. MMW Fortschritte der Medizin, 2011, Dec-01, Volume: 153, Issue:48 Topics: Anticoagulants; Controlled Clinical Trials as Topic; Coronary Thrombosis; Dose-Response Relationship, Drug; Humans; Morpholines; Myocardial Infarction; Risk Assessment; Rivaroxaban; Secondary Prevention; Survival Rate; Thiophenes	2011
Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:10 Topics: Acute Coronary Syndrome; Blood Platelets; Cell Adhesion Molecules; Coronary Thrombosis; Female; Follow-Up Studies; France; Hemorrhage; Humans; Kaplan-Meier Estimate; Linear Models; Male; Microfilament Proteins; Middle Aged; Multivariate Analysis; Myocardial Ischemia; Odds Ratio; Percutaneous Coronary Intervention; Phosphoproteins; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Time Factors; Treatment Outcome	2012
Abciximab for distal thromboaspiration catheter-related embolization in ST-segment elevated myocardial infarction. Archives of cardiovascular diseases, 2012, Volume: 105, Issue:11 Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Electrocardiography; Embolism; Enoxaparin; Female; Humans; Immunoglobulin Fab Fragments; Infusions, Parenteral; Injections, Intra-Arterial; Middle Aged; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Stents; Suction; Thiophenes; Thrombectomy	2012
Antiplatelet therapy: Does prasugrel or ticagrelor suffice in patients with STEMI? Nature reviews. Cardiology, 2013, Volume: 10, Issue:3 Topics: Adenosine; Coronary Thrombosis; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Thiophenes; Ticagrelor; Treatment Outcome	2013
[Prasugrel, a new thienopyridine]. Hamostaseologie, 2007, Volume: 27, Issue:5 Topics: Clinical Trials, Phase II as Topic; Clopidogrel; Coronary Thrombosis; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine	2007
Experimental evaluation of coronary thrombodynamics and effects of pharmacological interventions in acute coronary syndromes. Japanese circulation journal, 1992, Volume: 56, Issue:11 Topics: Animals; Antithrombins; Arginine; Coronary Circulation; Coronary Thrombosis; Dogs; Heparin; Myocardial Infarction; Pipecolic Acids; Sulfonamides; Thiophenes; Thrombolytic Therapy; Thromboxane-A Synthase; Urokinase-Type Plasminogen Activator	1992